Vor Biopharma (NASDAQ:VOR) Shares Down 5.4% – Here’s What Happened

Vor Biopharma Inc. (NASDAQ:VOR) was down 5.4% during trading on Wednesday . The stock traded as low as $23.59 and last traded at $23.7420. Approximately 192,494 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 1,028,723 shares. The stock had previously closed at $25.10.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Wall Street Zen raised shares of Vor Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Wedbush upped their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Vor Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $43.38.

Vor Biopharma Stock Down 3.9%

The stock has a 50-day simple moving average of $21.68 and a 200 day simple moving average of $17.40.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, sell-side analysts expect that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after acquiring an additional 4,144 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Vor Biopharma in the 3rd quarter valued at $230,000. BNP Paribas Financial Markets boosted its stake in shares of Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares in the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of Vor Biopharma in the 3rd quarter worth about $304,000. Finally, Engineers Gate Manager LP grew its holdings in shares of Vor Biopharma by 37.5% in the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock worth $680,000 after purchasing an additional 10,071 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).